Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Mangal Electrical IPO Review, Analysis, Good or Bad

By Jagat Joshi
August 19, 2025

The opening date of the Mangal Electrical IPO is August 20, 2025, while the closing date is August 22, 2025. The Mangal Electrical IPO price band is set between ₹533 to ₹561 per share. At the same time, the face value of the IPO is ₹10 each. The company filed a DRHP to raise funds of around ₹400 crores through an Initial public offering (IPO).

As an investor, deciding whether the IPO is Good or Bad to invest in can often be challenging. If you are confused and worried about whether to Apply or Not the Mangal Electrical IPO. Then worry not, here we are describing 10 important key points & an in-depth, detailed Mangal Electrical IPO review which will help you to make the decision.

Strengths and Weaknesses of Mangal Electrical IPO

Strengths:

Its promoters offer strong leadership, and it is backed by an experienced senior management team who have over 35 years of experience in the power infrastructure industry.

The company includes a diversified customer base, including customers spanning across India and the globe.

Mangal Electrical offers a proven track record of consistent growth, showcasing a strong market presence in the power infrastructure industry.

India’s substation capacity has grown strongly, showing the expansion of the country’s power infrastructure to meet rising electricity demand.

Weaknesses:

The company’s use of raw materials in manufacturing keeps changing due to many factors that are beyond its control. In case any rise or fluctuation in the prices of raw materials occurs, it can negatively impact the business, cash flow, and overall condition.

Any disruption, breakdown, or shutdown of our manufacturing facilities or OEM suppliers could seriously affect its business, finances, operations, and cash flow.

Mangal Electricals is mostly dependent on a limited number of customers, meaning in change in these customers can badly impact the cash flow, finances, and operations.

They do not hold fixed agreements with their customers or suppliers for products or raw materials. Unable to maintain these relationships can negatively impact the business, cash flow, and financial performance.

Mangal Electrical IPO Details

IPO Size	₹400 crores
Offer-for-sale	No Offer-for-Sale
Fresh issue	₹400 crores
Price band	₹533 to ₹561
Subscription	Opens on August 20, 2025, and the closing date is August 22, 2025
Purpose of IPO	Fresh Issue and No Offer-for-Sale

Mangal Electrical IPO Open and closing dates?

Mangal Electrical IPO will open for subscription on August 20, 2025, and will be closed for subscription on August 22, 2025.

What is the size of the Mangal Electrical IPO?

The company planned to raise around ₹400 crores in funds via IPO. This IPO comprises a fresh issue of ₹400 crores with no Offer-for-Sale component with a face value of ₹10 each.

What are the subscription details of the Mangal Electrical IPO?

The Mangal Electrical IPO price range is set at ₹533 to ₹561 per share. In this IPO, a total of 26 shares were available in 1 lot size for the minimum Retail category. For the maximum Retail category, 338 shares were available in 13 lot sizes. Additionally, 364 shares were available in 14 lot sizes for the S-HNI Minimum category. While for the B-HNI Minimum category, 1,794 shares were available in 69 lot sizes.

To invest in this IPO, each investor category has specific investment amounts:

Retail Investors: Minimum investment of ₹14,586 and maximum investment of ₹1,89,618.
Small HNI (S-HNI): Minimum investment of ₹2,04,204.
Big HSI (S-HNI): A minimum investment of ₹10,06,434 is required.

What is the Mangal Electrical IPO listing Date?

Mangal Electrical is a Mainboard IPO. Shares will be listed on August 28, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).

About Mangal Electrical

Founded in 2008, Mangal Electrical Industries Limited is one of the leading companies that is involved in the manufacturing of transformers, which are widely used for the distribution and transmission of electricity in the power sector. Mangal Electrical is engaged in the design of transformer parts that comprise laminations, CRGO slit coils, amorphous cores, coil and core assemblies, wound cores, toroidal cores, and oil-immersed circuit breakers.

The company manufactures transformers ranging from 5 KVA to 10 MVA. Moreover, it also provides EPC services for building electrical substations in the power sector. The company includes 761 permanent employees as of June 30, 2025. As of now, Mangal Electrical Industries runs 5 production units in Rajasthan with an annual capacity of 16,200 MT for CRGO, 750,000 KVA for transformers, 75,000 units for ICB, and 2,400 MT for amorphous units.

What are the Objectives of the Mangal Electrical IPO?

The proceeds raised from the fresh issue will be utilized for the Repayment/ prepayment of certain outstanding borrowings taken by the Company. Some funds will be used for the Capital expenditure, including civil works of the Company for expanding the facility at Unit IV situated at Reengus, Sikar District, Rajasthan. Lastly, the remaining funds will be used for the company’s General corporate purposes.

Mangal Electrical IPO Financials

The company reported revenue of ₹559.24 crores in 2025, whereas the company reported a profit is ₹47.29 crores in 2025.

Mangal Electrical IPO Promoters

Rahul Mangal, Ashish Mangal, Saroj Mangal, and Aniketa Mangal are the promoters of the company.

Who are the Mangal Electrical IPO lead managers and registrar?

Systematix Corporate Services Ltd is the lead manager of the issue, while Bigshare Services Pvt Limited is the company’s registrar.

Should you apply or not for the Mangal Electrical IPO?

Investors who see the power infrastructure sector as an interesting option can invest in this IPO. Mangal Electrical has been engaged in the processing of transformer components, its transformers range from single-phase 5 KVA to three-phase 10 MVA units. The company also trades in CRGO and CRNO coils, as well as amorphous ribbons.

Strong backward and forward integration, in-house capabilities for critical raw materials, and a strong position in supplying CRGO and transformer products are the strengths of the company. However, just like the strengths, each company comes with risks too, that are high dependency on limited customers, no long-term agreements with suppliers or buyers, and exposure to raw material price fluctuations, which an investor must keep in mind before investing their money in it.

So, now the question is, should you apply or not for the Mangal Electrical IPO? If you are looking to invest in a company that promotes client relationships, a highly diversified customer base, and a proven track record of consistent growth, then Mangal Electrical’s IPO could be a good long-term investment option.

However, we recommend always doing a good financial background check on the company you want to invest in, and investing in it at your own risk.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.

Jagat Joshi

Add IPOWatch to your Google News feed.

One Response

Chaitanya jain says:

August 20, 2025 at 1:51 PM

Numbers look good on paper, but maybe first settle pending salaries at child companies like Metadrob before asking the public to invest. Trust is built inside out.